Search
Selected Filter
Displaying 71–80 of 504 news results
-
Kiora Reports Vision Restoration in Phase 1/2 Clinical Trial for Photoswitch Therapy
Research NewsThe company’s molecule is designed to restore some vision to people with ultra-low or no vision caused by advanced retinitis pigmentosa and other retinal diseases.
-
New Report: Vitamin A Supplementation Provides No Vision Benefit to RP Patients
Research NewsThe report also concludes that vitamin E supplementation accelerates vision loss for RP patients
-
Foundation News
First of its Kind Collaboration Marries Genomics Data with World’s Largest Database of Ophthalmologic Patient Encounters to Improve Accuracy of Clinical Research.
-
Foundation Fighting Blindness Named Beneficiary for iDox Concert
Foundation NewsSpecial event being held during American Academy of Ophthalmology annual conference in San Francisco, California
-
Foundation Fighting Blindness and Eone Announce Partnership
Foundation NewsTogether, the Foundation Fighting Blindness and Eone are launching a new limited-edition tactile timepiece watch, the ChangeMaker.
-
Ocugen Reports Updated Results for Clinical Trial of Modifier Gene Therapy
Research NewsThe company is also launching modifier gene therapy clinical trials for GA and Stargardt disease
-
First Patient Dosed in LCA5 Gene Therapy Clinical Trial Launched by Opus Genetics
Research NewsOpus was established by the RD Fund, the Foundation’s venture philanthropy arm
-
Foundation Funds 25 New Grants Totaling $15.1 Million in FY23
Research NewsThe global leader in retinal degenerative disease research supports a total of 93 research grants in its portfolio.
-
Therapeutic Targets for Dry AMD: A Foundation Fighting Blindness Webinar for Eye Care Professionals
Foundation NewsThe free, online event will feature a lecture from David Boyer, MD, a Senior Partner at Retina-Vitreous Associates Medical Group and dry AMD expert.
-
SparingVision Recruiting for Clinical Trial of Cone-Preserving Gene Therapy for RP
Research NewsFirst cohort of patients has been dosed in Phase ½ clinical trial taking place in Pittsburgh and Paris
.png)
.png)
